Global Guerbet Alcohols Market Expected to Witness Significant Growth Owing to Soaring Multifunctional Cosmetics Demand

Guerbet alcohols are highly branched alcohols first developed by Marcel Guerbet in 1890s. Guerbet alcohols possess significantly low melting points as compared to linear alcohols with same number of C (carbon) atoms. Owing to their branching Guerbet alcohols possess high molecular weight and so they exhibit characteristics such as low irritation properties, extremely low melting points, low volatility, reactive and utilized for preparation of many derivatives, superfatting agents and, good lubricants. As Guerbet alcohols are essentially saturated they register good oxidative stability at high temperatures, possess excellent color initially & at high temperatures and exhibit improved stability in unsaturated products among many applications. Owing to these properties, Guerbet alcohols gain interest as compounds & raw materials for making derivatives.

Guerbet Alcohol to Register 5.6% CAGR During 2016 to 2024

The global market is being populated by enhanced beauty & conscious customers and the beauty & cosmetics industry is experiencing a massive boom. A large number of high-end beauty products & cosmetics form part of daily lives of millions of people. The necessity and emergence of multifunctional cosmetics are rising in the global cosmetics market. The new range of multifunctional cosmetics capable of omitting and controlling some acute skin problems are increasing in demand and geared to deal with issues such as anti-aging. They possess the ability of preventing skin from UV rays, act as an excellent anti-oxidant, moisturizers and possess the capability to clean the skin. This significant rise in multifunctional cosmetics market is expected to propel the growth of global Guerbet alcohols market in the near future. The global Guerbet alcohols market is projected to witness growth at 5.6% CAGR during 2016 to 2024 and reach a market value of US $1316.7 million by 2024 end according to a study by Persistence Market Research (PMR).

Long & Extensive Procedure of Guerbet Alcohol Manufacturing Expected to Impede its Market Growth

Guerbet alcohols are immensely prevalent within cosmetic fraternity and are safer alternatives. Guerbet alcohols’ genetic quality allows them to gain traction in the market. They act as excellent flattening & good perfuming agents as well as an able emulsion stabilizer making them an obvious choice for leading cosmetic giants across the globe. However, the production cost of Guerbet alcohols is extremely high. Going through a series of steps prior to reaching final stage, proper care & precaution are required for a suitable production of Guerbet alcohols. This long & extensive process for manufacturing Guerbet alcohols is likely to restrain the growth of global Guerbet alcohol market.

The Major Uses of Guerbet Alcohols Include

Components of cosmetics & lubricants, solvents for printing colors & inks

C-C chain length of Guerbet alcohols are utilized for production of specialty waxes & for cosmetics

2-Ethylhexanol, a derivative of Guerbet compound is used for the production of plasticizers and 2-ethylhexylate which is used in adhesives, coating materials and inks.

Guerbet chemistry provides a unique collection of starting materials for highly effective surfactants preparation & specialty materials preparation for several markets. The effect of branching on Guerbet surfactants’ performance properties is likely to result in continuous commercial development of products.

For more information visit


Global Cardiac Pacemaker Market Continues to Witness a Decline

Cardiac pacemaker is an implantable heart device for patients with bradycardia or slow heartbeat. A pacemaker helps in restoring heart’s rhythm by transmitting tiny electrical signals to heart. A pacing systems actually involves two by products viz. pacemaker and leads. A pacemaker is a small device implanted under the skin, usually below collarbone on the left/right side of the chest. A pacemaker continuously monitors the heart and sends out small electrical signals that are undetectable to correct a slow heart rate if detected. Leads include soft insulated wires carrying the electrical impulse from pacemaker to the heart and relaying information on heart’s natural activity back to pacemaker.

Factors influencing the growth of global cardiac pacemaker market include

  • High occurrences of diseases in underdeveloped economies
  • Increasing prevalence of cardiovascular disorders among developed economies
  • Several supportive government initiatives
  • Non-government organizations funding
  • Advanced Diagnostics
  • Favorable reimbursement treatment scenario
  • Cost-effective steps by several governments

Focus on approaches of new device launches and reliable, fast and cost-effective development of diagnostic methods is likely to fuel the global cardiac pacemaker market. However, the global cardiac pacemaker market is anticipated to witness a declining -0.5% CAGR during 2016 to 2024 according to the report by Persistence Market Research (PMR).

Abbott’s FDA Approved Wireless Pacemaker

The Food & Drug Administration (FDA) of U.S. approved Abbott’s tiny wireless pacemaker rendering it the longest-lasting and smallest MRI-compatible device. The new MRI-conditional labelling applies to pacing lead. With the acquisition of St. Jude Medical, Abbott picked up the Tendril MRI pacing lead and the Assurity MRI pacemaker. Abbott’s pacemaker enables physicians in monitoring the patients wirelessly reducing need for office visits. The new labelling denotes that patients implanted with these pacemakers, without fear of damaging the implant, may undergo diagnostic MRI scans.

At the time of MRI procedure, preprogrammed MRI implant settings are activated by a hand-held device. These settings, individualized to each patient, help in reducing the effort, inconvenience and time required for pre & postscan pacemaker reprogramming. This small wireless and long-lasting pacemaker, allowing patients to undergo MRI scans, is an instrumental step in growing forward the available patient treatment options.

Cedars-Sinai Heart Institute Investigators to Develop a Biological Pacemaker

Investigators from Cedars-Sinai Heart Institute, with $3 million grant from National Institutes of Health, are close to developing a biological pacemaker capable of treating patients with slow heartbeats. The novel, minimally-invasive gene therapy transforms the patient’s normal heart cells to pacemaker cells to regulate heart function. These pacemakers are likely to replace electronic pacemakers in the future. Specialized pacemaker cells naturally found in the heart generate electrical activity spreading throughout the heart tracing an orderly pattern and creating rhythmic muscle contractions, i.e. heartbeats. If pacemaker cells go askew, the heartbeats slow down resulting into fainting or sudden death. However, patients incline towards electronic pacemaker rendering it as the only treatment option while undergoing surgery.

Biological Pacemaker Expected to be Tested in Patients in Next Five Years

Cingolani, a practicing cardiac electrophysiologist, has significant experience on heart rhythm devices & their limitations. With his team of investigators, he is working on delivering gene directly to patient’s heart at the time of minimally invasive catheter-based procedure. This gene would then transmute normal heart cells into pacemaker cells enabling the heart to beat steadily. Previous efforts of new pacemaker cells generation resulted into heart muscle cells capable of beating on their own. While, other approaches utilized embryonic stem cells for deriving pacemaker cells. However, the risks related to contamination of cancerous cells remains a persistent hurdle in realizing a therapeutic potential of embryonic stem cell-based approach. The team from Cedars-Sinai were capable of creating pacemaker cells closely resembling native cells, free from risk of cancer. If upcoming safety studies stand successful, Cingolani states that testing of biological pacemaker in patients could be possible in next five years.

For more infroamtion visit

Application of Green LED Exposure for Treatment of Neuropathic Pain

Followed by cancer, diabetes is the most common symptom for neuropathic pain. Owing to prevalence of the painful diabetic neuropathy (16%) among the elderly population around the world suffering from diabetes, the global neuropathic pain market is likely to gain an uptick in the near future. Factors driving the global neuropathic pain market include novel treatment options approval for neuropathic pain, soaring demand for neuropathic pain treatment, growing number of pain management centers and increasing prevalence of cancer & diabetes. Patient awareness on neuropathic pain treatment, increasing demand for generic drugs and rapid product launches for neuropathic pain treatment are some trends observed in the global neuropathic pain market.

Global Neuropathic Pain Market to Witness 5.6% CAGR During 2016 to 2026

Reinforced healthcare infrastructure & well-established reimbursements are fuelling the growth of neuropathic pain market across the globe. Pharmaceutical companies are concentrating on improved drugs development for fulfilling unmet patient needs those suffering from neuropathic pain. The global neuropathic pain market was worth US $5200 million in 2015 and it is estimated to witness 5.6% CAGR during 2016 to 2024 according to the report by Persistence Market Research (PMR).

Green LED Exposure for Treatment of Neuropathic Pain

In the United States, more than 100 million people suffer from chronic pain which diminishes their productivity and quality of life, costing billions of dollars per year to manage medically. This has shattered emotional wellbeing of people and has resulted into suicides & accidental drug overdoses. However, researchers from University of Arizona have come up with a non-pharmacological approach for managing chronic pain by treating it with green LED (light-emitting diodes). The results of this study have appeared in the February 2017 edition of Journal Pain. The study reflects that rats prone to neuropathic pain bathed in green LED depicted more tolerance for tactile & thermal stimulus as compared to rats not bathed in green LED. While, in both cases, zero side-effects were observed and no visual or motor performance was impaired.

For receiving green LED exposure, one group of rats was placed in clear plastic containers affixed with green light-emitting diode strips allowing the rats to bathe in green light. Second group of rats was exposed to room light fitted with contact lenses allowing green spectrum wavelength to pass through. Both of these groups were benefitted by green LED exposure. However, a group of rats fitted with opaque contact lenses that blocked green light didn’t benefit from green LED exposure. The researchers are currently focusing on a clinical trial with the help of green LED therapy for people suffering from fibromyalgia (chronic pain’s common source).

Treatment of Severe Neuropathic Pain, If Ignored, Results into Permanent Nerve Damage

Tissues possess a nerve supply. When nerves are performing well, signals are sent from them which we interpret as pain. Neuropathic pain involves compression or irritation of the nerve and the nerve is injured. This results in nerves sending incorrect signals to remaining pain centres. This could possibly result in nerve function change at both site of injury as well as areas around injury. Treatment of mild nerve pain may be ignored but severe nerve pain, if ignored, may cause permanent nerve injuries. Prevention of nerve pain depends on the condition of pain. Some can be prevented by avoiding lifting of excessive weights while some can’t be prevented as they are associated with familial or genetic cause. The probability of patient suffering from nerve injury to regain the condition before the injury solemnly depends on severity of condition and the intensity of treatment’s effect. Generally it takes six weeks for the patients to recover from nerve injury. If the neuropathic pain persists, then for managing the pain, surgery is needed involving procedures for decompressing the nerve such as removing nerve injury source.

For more information visit

Global Hepatitis C Treatment Market to Witness 3.1% CAGR During 2016 to 2024

The increasing prevalence of hepatitis C is attributed to unsterilized medical equipment, sharing needles and blood transfusion from mother to newly born baby. Leading market players are concentrating on hepatitis C treatment medication development which is resulting into new product development. The number of hepatitis C patients is more in developing economies such as Brazil, India and China as compared to developed economies. Different countries have various regulation bodies that approve drugs for treatment of disease. Drugs are not easily approved by these regulation bodies resulting in product unavailability in the market.

However, several NGOs are creating awareness and educating the people for fighting against hepatitis C disease. This is expected to drive the overall market for hepatitis C treatment. The global hepatitis C treatment market is anticipated to reach a market value of US $71.13 billion by 2024 end and witness 3.1% CAGR during 2016 to 2024 according to the report by Persistence Market Research (PMR).

Hepatitis C: A Battleground For Lawsuits

Hepatitis C, the liver disease, is a battleground for lawsuits intending to reduce the cost of medicines for treatment of disease. In February itself, 5 suits were filed in Argentina and India claiming that the newest class of antiviral drugs’ doesn’t warrant 20-year patent monopoly sought by manufacturers in these countries. In the previous decade, successful challenges attributed to patents regarding HIV drugs provided poor nations with access to high-quality comprehensive copies of medications at significantly low prices. Driven by that success, same strategy is applied by activists on the new wave of hepatitis C drugs.

The standard 12-week treatment course for patients suffering from hepatitis C costs over average annual salary of people in middle-income economies. Experts of public-health covey that access expansion of drugs would result into immediate benefits. Approximately 177.5 million adults across the globe suffer from hepatitis C which can result into cirrhosis or liver cancer if treatment is ignored. However the care is revolutionized owing to latest antiviral medications.

pCPA’s Agreement With Six Breakthrough Hepatitis C Medication Makers to Fight Against the Spread of Disease

The Canadian provinces had a pact with three pharmaceutical companies for the cost reduction in ultra-expensive drugs which has resulted into public funding for medications for thousands of Canadians suffering from mild chronic hepatitis C disease. The pan-Canadian Pharmaceutical Alliance, negotiating prices for provincial & territorial public drug programs, made an announcement on Tuesday regarding an agreement with six breakthrough makers of hepatitis C medications including Sovaldi and Harvoni.

A short time after pCPA’s confirmation of the deal, the British Columbia government made a declaration that its PharmaCare program will commence enveloping the drugs for people with chronic hepatitis C, in spite of its type and severity, in 2018. This is an important deflection from British Columbia’s present policy restricting public funding of drugs to people with particular genotypes of advanced liver scarring and hepatitis C. The latest generation of direct-acting antivirals of hepatitis C is an impressive improvement compared to traditional treatments.

San Francisco to Come Up with An Effective Treatment for Wiping Out Hepatitis C infection In Next Ten Years

San Francisco is on the verge of transmuting into the first city in U.S. in eliminating hepatitis C owing to its ambitious plan of curing every individual suffering from it and restricting the spread of this infectious disease which may result into severe liver damage. An effective and easy to take new cure along with rising enthusiasm for programs on increasing healthcare access has convinced public health officials and doctors that the virus can be wiped out over the next ten years. The key role of the plan is identifying individuals infected by hepatitis C while convincing insurers in funding the significantly expensive treatment. Hepatitis C forms a part of family of viruses causing inflammation in liver and other systemic problems of the human body. The transmission of virus takes course through blood, similar to HIV, even though hepatitis C virus is more infectious than HIV virus.

For more information visit

Top 3 Factors Shaping Trends of Global Automated Endoscope Reprocessor Market

Complex surgeries such as duodenoscope among other endoscopes such as colonoscopies and gastroscopes have compelled hospitals to adopt automated endoscope reprocessor devices. In addition, surge in hospitalization due to biliary tract and pancreatic problems has increased the count of ERCP surgeries in the hospitals. Surge in number of cases of ERCP has further contributed towards growth of the global automated endoscope reprocessor market.

Segmentation Analysis

Single basin automated endoscope reprocessors among other types of products will retain dominance in terms of revenue and will witness a relatively high growth rate at 8.6% CAGR in the span of next eight years. Whereas, the standalone automated endoscope reprocessors among other types of modalities will witness an increase of 1.7X in the coming years. In 2016, hospitals among other end users accounted for a revenue share of 65.6% in the global automated endoscope reprocessor market.

Market Trends

Attributed to growing preference of hospitals and patients, the automated endoscope reprocessor devices will witness an upsurge in demand in the coming years. In addition, hospitals are striving to control and prevent infections, and further maintain a healthy environment in the hospitals. Such factors are likely to fuel demand of the automated endoscope reprocessor devices in the coming years. However, complicated procedures related to endoscopy and associated risks add to the list of factors inhibiting growth of the automated endoscope reprocessor market globally in the span of next eight years.

Hospitals among various end users accounted for a revenue share of 65.6% of the automated endoscope reprocessor market globally in 2016. Moreover, registering an attractiveness index of 2.6, hospitals among other end users will represent the most attractive segment in the span of next eight years.

Additionally, robust support for healthcare infrastructure in parallel to growing concerns regarding safety of patients will boost demand for automated endoscope reprocessor devices in ambulatory surgical centres, clinics and hospitals. Furthermore, adding to the count of surgical procedures in parallel to growing population will fuel growth of the automated endoscope reprocessor market globally in the coming years.

Single basin automated endoscope reprocessors among other types of products will retain dominance in terms of revenue in the automated endoscope reprocessor market globally in the span of eight years. Moreover, single basin automated endoscope reprocessors will witness relatively high growth rate of 8.6% CAGR in the coming years. Whereas among other types of modalities, standalone automated endoscope reprocessors will represent an attractive segment in the global automated endoscope reprocessor market in the span of next eight years. In addition, revenues generated from standalone automated endoscope reprocessors will witness an increase of 1.7X in the coming years as compare to 2016.

Regional Analysis

The North America automated endoscope reprocessor market will account for a revenue share of 41.2% by the end of 2016. Moreover, the North America automated endoscope reprocessor market will grow at a healthy CAGR of 8.2% in the span of next eight years. In addition, the automated endoscope reprocessor market in Europe will represent the second most lucrative market globally among other regions in the coming years. Furthermore, the automated endoscope reprocessor market in Europe will represent an absolute $ opportunity of US$ 13.6 Mn in 2017 over 2016. However, the Asia Pacific automated endoscope reprocessor market will grow at 6.7% CAGR and reach US$ 210.2 Mn in the span of next eight years.

In 2015, leading market players such as Olympus Corporation accounted for major revenue share in the global automated endoscope reprocessor market. Whereas, Steris Plc., Advanced Sterilization Products Services Inc. (subsidiary of Johnson & Johnson) and Cantel Medical have a wide product portfolio in the automated endoscope reprocessor market globally.

For more information visit